1. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab. Issue 1 (7th December 2017) Authors: Tweehuysen, Lieke; van den Bemt, Bart J. F.; van Ingen, Iris L.; de Jong, Alphons J. L.; van der Laan, Willemijn H.; van den Hoogen, Frank H. J.; den Broeder, Alfons A. Journal: Arthritis & rheumatology Issue: Volume 70:Issue 1(2018) Page Start: 60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗